3-乙氧基氮杂环丁烷 | 88536-21-4

• 物质功能分类: 有机原料 - 烃类化合物及其衍生物 - 环烃
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氮杂环丁烷
• 中文名称: 3-乙氧基氮杂环丁烷
• 中文别名: 3-乙氧基氮杂丁烷；3-乙氧基吖丁啶
• 英文名称: 3-ethoxyazetidine
• CAS: 88536-21-4
• 化学式: C₅H₁₁NO
• 分子量: 101.148
• InChiKey: MIGAFYXADJBZDV-UHFFFAOYSA-N

物化性质

• 密度：
  0.94

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  7
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  21.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  3-乙氧基氮杂环丁烷 在 5% Pd(II)/C(eggshell) 、 氢气 、 三乙胺 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 生成 6-(3-Ethoxyazetidin-1-yl)pyridin-3-amine
  参考文献：
  名称：

  Discovery of Orally Active Carboxylic Acid Derivatives of 2-Phenyl-5-trifluoromethyloxazole-4-carboxamide as Potent Diacylglycerol Acyltransferase-1 Inhibitors for the Potential Treatment of Obesity and Diabetes

  摘要：

  Diacylglycerol acyltransferase-1 (DGAT-1) is the enzyme that catalyzes the final and committed step of triglyceride formation, namely, the acylation of diacylglycerol with acyl coenzyme A. DGAT-1 deficient mice demonstrate resistance to weight gain on high fat diet, improved insulin sensitivity, and reduced liver triglyceride content. Inhibition of DGAT-1 thus represents a potential novel approach for the treatment of obesity, dyslipidemia, and metabolic syndrome. In this communication, we report the identification of the lead structure 6 and our lead optimization efforts culminating in the discovery of potent, selective, and orally efficacious carboxylic acid derivatives of 2-phenyl-5-trifluoromethyloxazole-4-carboxarnides. In particular, compound 29 (DGAT-1 enzyme assay, IC(50) = 57 nM; CHO-K1 cell triglyceride formation assay, EC(50) = 0.5 mu M) demonstrated dose dependent inhibition of weight gain in diet induced obese (DIO) rats (0.3, 1, and 3 mg/kg, PO, qd) during a 21-day efficacy study. Furthermore, compound 29 demonstrated improved glucose tolerance determined by an oral glucose tolerance test (OGTT).

  DOI：

  10.1021/jm101580m
• 作为产物：
  描述：

  1-Benzhydryl-3-ethoxyazetidin 在 氢气 、 palladium(II) hydroxide 、 溶剂黄146 作用下， 以 甲醇 为溶剂， 反应 6.0h， 以1 g的产率得到3-乙氧基氮杂环丁烷
  参考文献：
  名称：

  4,5,6-TRI-SUBSTITUTED INDAZOLES DERIVATIVES, PREPARATION THEREOF, AND USE THEREOF IN MEDICINES

  摘要：

  提供了4,5,6-三取代吲唑衍生物，其制备方法以及在药物中的用途。具体来说，提供了式（I）化合物或药用可接受的盐、立体异构体、溶剂合物或前药，其制备方法以及在药物中的用途。

  公开号：

  EP3441388A1

文献信息

• Tetrahydrochromenoimidazoles as Potassium-Competitive Acid Blockers (P-CABs): Structure−Activity Relationship of Their Antisecretory Properties and Their Affinity toward the hERG Channel
  作者：Andreas M. Palmer、Vittoria Chiesa、Anja Schmid、Gabriela Münch、Burkhard Grobbel、Peter J. Zimmermann、Christof Brehm、Wilm Buhr、Wolfgang-Alexander Simon、Wolfgang Kromer、Stefan Postius、Jürgen Volz、Dietmar Hess

  DOI：10.1021/jm100040c

  日期：2010.5.13

  Potassium-competitive acid blockers (P-CABs) constitute a new therapeutic option for the treatment of acid-related diseases that are widespread and constitute a significant economical burden. Enantiomerically pure tetrahydrochromenoimidazoles were prepared using the readily available candidate 4 (BYK 405879) as starting material or the Noyori asymmetric reduction of ketones as key reaction. A comprehensive

  钾竞争性酸阻滞剂（P-CAB）构成了治疗与酸有关的疾病的新的治疗选择，这些疾病与疾病相关的疾病广泛且构成重大的经济负担。使用容易获得的候选物4制备对映体纯的四氢色氮咪唑（BYK 405879）作为起始原料或Noyori酮的不对称还原是关键反应。建立了关于5-羧酰胺和8-芳基残基对体外活性，Ghosh Schild大鼠体内酸抑制和对hERG通道的亲和力影响的综合SAR。此外，通过瘘管犬的24 h pH测量，检查了最有希望的目标化合物的抗分泌作用的功效和持续时间，与Ghosh Schild大鼠相比，观察到了明显不同的SAR。鉴定了几种与候选物4具有可比性的四氢色氮咪唑。
• [EN] RECEPTOR-INTERACTING PROTEIN 1 INHIBITORS INCLUDING PIPERAZINE HETEROCYCLIC AMIDE UREAS<br/>[FR] INHIBITEURS DE PROTÉINE 1 INTERAGISSANT AVEC LE RÉCEPTEUR COMPRENANT DES URÉES AMIDES HÉTÉROCYCLIQUES DE PIPÉRAZINE
  申请人：SIRONAX LTD

  公开号：WO2021233394A1

  公开（公告）日：2021-11-25

  The present disclosure provides compounds including piperazine heterocyclic amide urea compounds that inhibit cellular necrosis and/or human receptor interacting protein 1 kinase (RIP1), including corresponding sulfonamides, and pharmaceutically acceptable salts, hydrates and stereoisomers thereof. The compounds are employed in pharmaceutical compositions, and methods of making and use, including treating a person in need thereof with an effective amount of the compound or composition, and detecting a resultant improvement in the person's health or condition.

  本公开提供了包括哌嗪杂环酰胺脲类化合物在内的化合物，可以抑制细胞坏死和/或人类受体相互作用蛋白1激酶（RIP1），包括相应的磺酰胺和药用可接受的盐、水合物和立体异构体。这些化合物用于制备药物组合物，并用于制备和使用方法，包括使用有效量的化合物或组合物治疗需要的人，并检测人体健康或状况的改善。
• Pyridonecarboxylic acids as antibacterial agents. Synthesis and antibacterial activity of 7-(3-amino-1-pyrrolidinyl)-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid and its analogs
  作者：Hiroshi Egawa、Teruyuki Miyamoto、Akira Minamida、Yoshiro Nishimura、Hidetsugu Okada、Hitoshi Uno、Junichi Matsumoto

  DOI：10.1021/jm00378a004

  日期：1984.12

  8-naphthyridine-3- carboxylic acids and their ethyl esters (3-7) with cyclic amines such as 3-aminopyrrolidine. The N-1 substituent includes ethyl, vinyl, and 2-fluoroethyl groups. As a result of in vitro and in vivo antibacterial screenings, three compounds, 1-ethyl- and 1-vinyl-7-(3-amino-1-pyrrolidinyl)-6-fluoro- 1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acids (33a and 33b) and 1-vinyl-7-

  用1-取代的7-氯-，7-（乙基磺酰基）-和7-（甲苯磺酰氧基）-制备在C-7具有氨基和/或羟基取代的环状氨基的标题化合物（28-56）。 6-氟-1,4-二氢-4-氧代-1,8-萘啶-3-羧酸及其乙酯（3-7）与环状胺，例如3-氨基吡咯烷。N-1取代基包括乙基，乙烯基和2-氟乙基。作为体外和体内抗菌筛选的结果，三种化合物，1-乙基和1-乙烯基-7-（3-氨基-1-吡咯烷基）-6-氟-1,4-二氢-4-氧代-发现1,8-萘啶-3-羧酸（33a和33b）和1-乙烯基-7- [3-（甲基氨基）-1-吡咯烷基]类似物34b具有比依诺沙星（2）更高的活性。值得进一步的生物学研究。讨论了构效关系。
• Piperazinyl-glutamate-pyrimidines as potent P2Y12 antagonists for inhibition of platelet aggregation
  作者：John J. Parlow、Mary W. Burney、Brenda L. Case、Thomas J. Girard、Kerri A. Hall、Ronald R. Hiebsch、Rita M. Huff、Rhonda M. Lachance、Deborah A. Mischke、Stephen R. Rapp、Rhonda S. Woerndle、Michael D. Ennis

  DOI：10.1016/j.bmcl.2009.09.017

  日期：2009.11

  Piperazinyl-glutamate-pyrimidines were prepared with oxygen, nitrogen, and sulfur substitution at the 4-position of the pyrimidine leading to highly potent P2Y(12) antagonists. In particular, 4-substituted piperidine-4-pyrimidines provided compounds with exceptional potency. Pharmacokinetic and physicochemical properties were fine-tuned through modi. cations at the 4-position of the piperidine ring leading to compounds with good human PRP potency, selectivity, clearance and oral bioavailability. (c) 2009 Elsevier Ltd. All rights reserved.
• 4,5,6-TRI-SUBSTITUTED INDAZOLES DERIVATIVES, PREPARATION THEREOF, AND USE THEREOF IN MEDICINES
  申请人：Shanghai Haiyan Pharmaceutical Technology Co., Ltd.

  公开号：EP3441388A1

  公开（公告）日：2019-02-13

  Provided are 4,5,6-tri-substituted indazoles derivatives, a preparation method therefor, and a use thereof in medicines. Specifically, provided are compounds of formula (I) or pharmaceutically acceptable salts, stereoisomers, solvates, or prodrugs thereof, a preparation method therefor, and a use thereof.

  提供了4,5,6-三取代吲唑衍生物，其制备方法以及在药物中的用途。具体来说，提供了式（I）化合物或药用可接受的盐、立体异构体、溶剂合物或前药，其制备方法以及在药物中的用途。